NCT07221123 Boosting Olfactory and Sensory Training Study (BOOST)
| NCT ID | NCT07221123 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Alabama at Birmingham |
| Condition | HIV (Human Immunodeficiency Virus) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-05-02 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2026-05-02 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Conventional Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Scented Marker Training at Home -- Several marker scents in which they will smell twice a day for 8 weeks.
Eligibility Criteria
Inclusion Criteria: * Participants (men \& women) must be 40+ years * have cognitive complaints. * must be proficient in English Exclusion Criteria: * a sinus infection (within the past 3 months), thrush, candidiasis, pregnant, current cold or flu, hay fever, asthma, nasal allergies, opportunistic infections (including COVID-19) within the past 3 months, or current nasal obstruction condition. * Participation requires \~8 weeks and in-person visits, participants living beyond 60 miles away from the center will be excluded. * Participants living in unstable housing (e.g., shelter) or with significant neuro-comorbidities (e.g., schizophrenia) will be excluded. * Other conditions (e.g., legally blind/deaf, currently undergoing radiation or chemotherapy, or a history of significant brain trauma) that could impact olfactory and cognitive testing also necessitate exclusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07221123 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying HIV (Human Immunodeficiency Virus). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07221123 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07221123 currently recruiting?
Yes, NCT07221123 is actively recruiting participants. Contact the research team at devance@uab.edu for enrollment information.
Where is the NCT07221123 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT07221123 clinical trial?
NCT07221123 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.